# NCT05599984 (NCT05599984)

> Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05599984
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Advanced Solid Tumors
- Interventions: ABBV-706; Cisplatin; Budigalimab; Carboplatin
- Enrollment: 288
- Primary outcome: Percentage of Participants With Adverse Events (AE)
- Primary outcome: Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706
- Primary outcome: Time to Cmax (Tmax) of ABBV-706
- Primary outcome: Terminal Phase Elimination Half-Life (t1/2) of ABBV-706
- Primary outcome: Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706
- Primary outcome: Antidrug Antibodies (ADAs)
- Primary outcome: Neutralizing Antibodies (nAbs)
- Primary outcome: Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors
- Primary outcome: Recommended Phase 2 Dose (RP2D) of ABBV-706
- Primary outcome: Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors
- Primary outcome: Duration of response (DOR) for Participants with Confirmed CR/PR
- Primary outcome: Percentage of Participants with Clinical Benefit
- Primary outcome: Progression-Free Survival (PFS)
- Primary outcome: Overall survival (OS)

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05599984